Arcus Biosciences
Arcus Biosciences

Arcus Biosciences

Biotechnology
WebsiteInvestor RelationsSEC
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

$2.6B

Market Cap • 11/5/2026

2015

(11 years)

Founded

2018

(8 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

7,2

P/S

25,8

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,5

EPS

—

Market Cap

Market Cap

2,6B

EV

2B

EV/Revenue

20,5

EV/EBITDA

-4,4

EV/EBIT

-4,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-12,1%

Total Yield

-12,1%

Payout

0%

Retained Earnings

-1,8B

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

473%

Capex/Revenue

1%

Capex/D&A

10%

Capex/OCF

-0,2%

SBC/OCF

—

% PPE

4%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

21,4%

CAGR Op. Income 5Y

11,2%

CAGR Net Income 5Y

10,2%

CAGR EPS 5Y

-2,4%

CAGR OCF 5Y

13,8%

Leverage

N.D./EBITDA

1,1

Debt/Equity

0%

Current Ratio

3,3

Quick Ratio

3,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium